These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23653047)

  • 21. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
    Watanabe A; Kotsuma M
    Drug Metab Pharmacokinet; 2024 Apr; 55():101000. PubMed ID: 38458122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
    Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
    Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
    Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.
    Hafner V; Albermann N; Haefeli WE; Ebinger F
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4172-4. PubMed ID: 18794387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voriconazole pharmacokinetics and pharmacodynamics in children.
    Neely M; Rushing T; Kovacs A; Jelliffe R; Hoffman J
    Clin Infect Dis; 2010 Jan; 50(1):27-36. PubMed ID: 19951112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Apr; 79(4):362-70. PubMed ID: 16580904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
    Purkins L; Wood N; Kleinermans D; Love ER
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.
    Hohmann N; Kreuter R; Blank A; Weiss J; Burhenne J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2017 Sep; 83(9):1954-1965. PubMed ID: 28370390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of grapefruit juice on serum voriconazole concentrations in the mouse.
    Sugar AM; Liu XP
    Med Mycol; 2000 Jun; 38(3):209-12. PubMed ID: 10892988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.
    Hohmann N; Kocheise F; Carls A; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Clin Pharmacokinet; 2016 Dec; 55(12):1535-1545. PubMed ID: 27236320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax.
    Dong J; Liu SB; Rasheduzzaman JM; Huang CR; Miao LY
    Pharm Res; 2022 Aug; 39(8):1921-1933. PubMed ID: 35725843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
    Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
    Stader F; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.